Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide

[1]  C. Lodeiro,et al.  The use of nanoparticles for targeted drug delivery in non-small cell lung cancer , 2023, Frontiers in Oncology.

[2]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[3]  Caicun Zhou,et al.  Non‐small cell lung cancer in China , 2022, Cancer communications.

[4]  Tianfeng Chen,et al.  Engineering cancer cell membrane-camouflaged metal complex for efficient targeting therapy of breast cancer , 2022, Journal of Nanobiotechnology.

[5]  Chen Wang,et al.  A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer. , 2022, International journal of pharmaceutics.

[6]  Hong Yuan,et al.  Cell membrane coated-nanoparticles for cancer immunotherapy , 2022, Acta pharmaceutica Sinica. B.

[7]  A. Guo,et al.  CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma , 2021, Molecular therapy. Nucleic acids.

[8]  S. Zaib,et al.  Histone modifications and their role in epigenetics of cancer. , 2021, Current medicinal chemistry.

[9]  Zihao Lu,et al.  Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA. , 2021, Chemico-biological interactions.

[10]  X. Qu,et al.  Cell membrane–camouflaged liposomes for tumor cell–selective glycans engineering and imaging in vivo , 2021, Proceedings of the National Academy of Sciences.

[11]  Lin Hu,et al.  Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. , 2021, Cancer letters.

[12]  Bin Liu,et al.  A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway. , 2021, Journal of materials chemistry. B.

[13]  Xing-jie Liang,et al.  Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair–inhibiting (HYDRI) nanomedicine , 2021, Science Advances.

[14]  Guo Chen,et al.  Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer , 2021, Aging.

[15]  Zhenqing Feng,et al.  Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells , 2021, Molecular therapy. Nucleic acids.

[16]  S. Hong,et al.  A novel PPARɣ ligand, PPZ023, overcomes radioresistance via ER stress and cell death in human non-small-cell lung cancer cells , 2020, Experimental & Molecular Medicine.

[17]  C. Esposito,et al.  Advances in Oligonucleotide Aptamers for NSCLC Targeting , 2020, International journal of molecular sciences.

[18]  G. Sethi,et al.  Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance , 2020, International journal of molecular sciences.

[19]  Yu Zhang,et al.  Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression , 2020, Cell Death & Disease.

[20]  Yanjuan Zhou,et al.  A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib , 2020, Translational cancer research.

[21]  Zhe Zhang,et al.  EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression , 2019, OncoTargets and therapy.

[22]  P. Leng,et al.  Aberrant N-cadherin expression in cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  G. Liskayová,et al.  pH sensitive N,N-dimethylalkane-1-amine N-oxides in DNA delivery: from structure to transfection efficiency. , 2019, Langmuir : the ACS journal of surfaces and colloids.

[24]  Jang-Yang Chang,et al.  New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment , 2019, International journal of molecular sciences.

[25]  M. Ahn,et al.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Katsuya Kobayashi,et al.  The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells , 2019, Pharmaceutical development and technology.

[27]  Kun Xu,et al.  LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC , 2019, Molecular therapy. Nucleic acids.

[28]  M. Dandapani,et al.  Epigenetic therapy for ovarian cancer: promise and progress , 2019, Clinical Epigenetics.

[29]  Wei Gao,et al.  The functional role of NGFR in regulating chemosensitivity in nasopharyngeal carcinoma. , 2018, Annals of Oncology.

[30]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[31]  U. Testa,et al.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells , 2018, Cancers.

[32]  C. Gridelli,et al.  Frontline immunotherapy for NSCLC: alone or not alone? , 2018, Nature Reviews Clinical Oncology.

[33]  Ruifeng Lu,et al.  A central role for cadherin signaling in cancer. , 2017, Experimental cell research.

[34]  Yongzhuo Huang,et al.  Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer , 2017, Cancer biology & medicine.

[35]  Yaping Li,et al.  Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer. , 2016, ACS nano.

[36]  L. Amable.  Cisplatin resistance and opportunities for precision medicine. , 2016, Pharmacological research.

[37]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[38]  Hongqing Zhao,et al.  Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis , 2016, Scientific Reports.

[39]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Qing-Wei Zhang,et al.  siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[41]  Chunhua Xu,et al.  Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. , 2014, Lung cancer.

[42]  L. Galluzzi,et al.  Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.

[43]  J. Ljubimova,et al.  Nanomedicine therapeutic approaches to overcome cancer drug resistance. , 2013, Advanced drug delivery reviews.

[44]  Edina M K da Silva,et al.  Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. , 2013, The Cochrane database of systematic reviews.

[45]  P. Postmus,et al.  Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). , 2013, Cancer treatment reviews.

[46]  X. Qiu,et al.  Prognostic Significance of Twist and N-Cadherin Expression in NSCLC , 2013, PloS one.

[47]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[48]  Liangfang Zhang,et al.  Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. , 2012, Biochemical pharmacology.

[49]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[50]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[51]  Huqun,et al.  Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer , 2012, Cancer.

[52]  A. Satelli,et al.  Vimentin in cancer and its potential as a molecular target for cancer therapy , 2011, Cellular and Molecular Life Sciences.

[53]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[54]  Robert Brown,et al.  Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2 , 2011, Molecular Cancer Therapeutics.

[55]  Jing Wang,et al.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[56]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[57]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[58]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[59]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[60]  H. Farhood,et al.  The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. , 1995, Biochimica et biophysica acta.